Mylan, Others To Pay $124M Over Medicaid Rebates

By Julie Zeveloff

Law360, New York (October 19, 2009, 5:56 PM ET) -- Mylan Inc. and several other pharmaceutical companies will pay a combined sum of $124 million to settle allegations that they bilked state Medicaid programs of millions of dollars by improperly classifying certain drugs for rebate purposes.

The U.S. Department of Justice on Monday announced the settlement, which resolves pending litigation in the U.S. District Court for the District of New Hampshire. The case, initially filed as a whistleblower suit by a Florida-based pharmacy, accused Mylan, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals LP and Ortho-McNeil Pharmaceutical of violating the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles